182 related articles for article (PubMed ID: 22574943)
1. Safety study of adeno-associated virus serotype 2-mediated human acid sphingomyelinase expression in the nonhuman primate brain.
Salegio EA; Samaranch L; Jenkins RW; Clarke CJ; Lamarre C; Beyer J; Kells AP; Bringas J; Sebastian WS; Richardson RM; Rosenbluth KH; Hannun YA; Bankiewicz KS; Forsayeth J
Hum Gene Ther; 2012 Aug; 23(8):891-902. PubMed ID: 22574943
[TBL] [Abstract][Full Text] [Related]
2. Magnetic resonance imaging-guided delivery of adeno-associated virus type 2 to the primate brain for the treatment of lysosomal storage disorders.
Salegio EA; Kells AP; Richardson RM; Hadaczek P; Forsayeth J; Bringas J; Sardi SP; Passini MA; Shihabuddin LS; Cheng SH; Fiandaca MS; Bankiewicz KS
Hum Gene Ther; 2010 Sep; 21(9):1093-103. PubMed ID: 20408734
[TBL] [Abstract][Full Text] [Related]
3. Adeno-associated viral vector serotype 9-based gene therapy for Niemann-Pick disease type A.
Samaranch L; Pérez-Cañamás A; Soto-Huelin B; Sudhakar V; Jurado-Arjona J; Hadaczek P; Ávila J; Bringas JR; Casas J; Chen H; He X; Schuchman EH; Cheng SH; Forsayeth J; Bankiewicz KS; Ledesma MD
Sci Transl Med; 2019 Aug; 11(506):. PubMed ID: 31434754
[TBL] [Abstract][Full Text] [Related]
4. AAV vector-mediated correction of brain pathology in a mouse model of Niemann-Pick A disease.
Passini MA; Macauley SL; Huff MR; Taksir TV; Bu J; Wu IH; Piepenhagen PA; Dodge JC; Shihabuddin LS; O'Riordan CR; Schuchman EH; Stewart GR
Mol Ther; 2005 May; 11(5):754-62. PubMed ID: 15851014
[TBL] [Abstract][Full Text] [Related]
5. Gene transfer of human acid sphingomyelinase corrects neuropathology and motor deficits in a mouse model of Niemann-Pick type A disease.
Dodge JC; Clarke J; Song A; Bu J; Yang W; Taksir TV; Griffiths D; Zhao MA; Schuchman EH; Cheng SH; O'Riordan CR; Shihabuddin LS; Passini MA; Stewart GR
Proc Natl Acad Sci U S A; 2005 Dec; 102(49):17822-7. PubMed ID: 16301517
[TBL] [Abstract][Full Text] [Related]
6. Combination brain and systemic injections of AAV provide maximal functional and survival benefits in the Niemann-Pick mouse.
Passini MA; Bu J; Fidler JA; Ziegler RJ; Foley JW; Dodge JC; Yang WW; Clarke J; Taksir TV; Griffiths DA; Zhao MA; O'Riordan CR; Schuchman EH; Shihabuddin LS; Cheng SH
Proc Natl Acad Sci U S A; 2007 May; 104(22):9505-10. PubMed ID: 17517638
[TBL] [Abstract][Full Text] [Related]
7. Merits of combination cortical, subcortical, and cerebellar injections for the treatment of Niemann-Pick disease type A.
Bu J; Ashe KM; Bringas J; Marshall J; Dodge JC; Cabrera-Salazar MA; Forsayeth J; Schuchman EH; Bankiewicz KS; Cheng SH; Shihabuddin LS; Passini MA
Mol Ther; 2012 Oct; 20(10):1893-901. PubMed ID: 22828503
[TBL] [Abstract][Full Text] [Related]
8. Intracerebral transplantation of adult mouse neural progenitor cells into the Niemann-Pick-A mouse leads to a marked decrease in lysosomal storage pathology.
Shihabuddin LS; Numan S; Huff MR; Dodge JC; Clarke J; Macauley SL; Yang W; Taksir TV; Parsons G; Passini MA; Gage FH; Stewart GR
J Neurosci; 2004 Nov; 24(47):10642-51. PubMed ID: 15564580
[TBL] [Abstract][Full Text] [Related]
9. Retroviral-mediated transfer of the human acid sphingomyelinase cDNA: correction of the metabolic defect in cultured Niemann-Pick disease cells.
Suchi M; Dinur T; Desnick RJ; Gatt S; Pereira L; Gilboa E; Schuchman EH
Proc Natl Acad Sci U S A; 1992 Apr; 89(8):3227-31. PubMed ID: 1565614
[TBL] [Abstract][Full Text] [Related]
10. AAV8-mediated hepatic expression of acid sphingomyelinase corrects the metabolic defect in the visceral organs of a mouse model of Niemann-Pick disease.
Barbon CM; Ziegler RJ; Li C; Armentano D; Cherry M; Desnick RJ; Schuchman EH; Cheng SH
Mol Ther; 2005 Sep; 12(3):431-40. PubMed ID: 16099409
[TBL] [Abstract][Full Text] [Related]
11. Fluorescence-based selection of retrovirally transduced cells in the absence of a marker gene: direct selection of transduced type B Niemann-Pick disease cells and evidence for bystander correction.
Yeyati PL; Agmon V; Fillat C; Dinur T; Dagan A; Desnick RJ; Gatt S; Schuchman EH
Hum Gene Ther; 1995 Aug; 6(8):975-83. PubMed ID: 7578419
[TBL] [Abstract][Full Text] [Related]
12. Intraparenchymal injections of acid sphingomyelinase results in regional correction of lysosomal storage pathology in the Niemann-Pick A mouse.
Yang WW; Dodge JC; Passini MA; Taksir TV; Griffiths D; Schuchman EH; Cheng SH; Shihabuddin LS
Exp Neurol; 2007 Oct; 207(2):258-66. PubMed ID: 17686472
[TBL] [Abstract][Full Text] [Related]
13. Safety of direct administration of AAV2(CU)hCLN2, a candidate treatment for the central nervous system manifestations of late infantile neuronal ceroid lipofuscinosis, to the brain of rats and nonhuman primates.
Hackett NR; Redmond DE; Sondhi D; Giannaris EL; Vassallo E; Stratton J; Qiu J; Kaminsky SM; Lesser ML; Fisch GS; Rouselle SD; Crystal RG
Hum Gene Ther; 2005 Dec; 16(12):1484-503. PubMed ID: 16390279
[TBL] [Abstract][Full Text] [Related]
14. Comparative analysis of acid sphingomyelinase distribution in the CNS of rats and mice following intracerebroventricular delivery.
Treleaven CM; Tamsett T; Fidler JA; Taksir TV; Cheng SH; Shihabuddin LS; Dodge JC
PLoS One; 2011 Jan; 6(1):e16313. PubMed ID: 21283548
[TBL] [Abstract][Full Text] [Related]
15. Ex vivo gene therapy using bone marrow-derived cells: combined effects of intracerebral and intravenous transplantation in a mouse model of Niemann-Pick disease.
Jin HK; Schuchman EH
Mol Ther; 2003 Dec; 8(6):876-85. PubMed ID: 14664789
[TBL] [Abstract][Full Text] [Related]
16. Slow AAV2 clearance from the brain of nonhuman primates and anti-capsid immune response.
Samaranch L; Hadaczek P; Kells AP; Bringas JR; Stockinger D; San Sebastian W; Macayan M; Samineni S; Pivirotto P; Forsayeth J; Bankiewicz KS
Gene Ther; 2016 Apr; 23(4):393-8. PubMed ID: 26510688
[TBL] [Abstract][Full Text] [Related]
17. Long-term expression and safety of administration of AAVrh.10hCLN2 to the brain of rats and nonhuman primates for the treatment of late infantile neuronal ceroid lipofuscinosis.
Sondhi D; Johnson L; Purpura K; Monette S; Souweidane MM; Kaplitt MG; Kosofsky B; Yohay K; Ballon D; Dyke J; Kaminksy SM; Hackett NR; Crystal RG
Hum Gene Ther Methods; 2012 Oct; 23(5):324-35. PubMed ID: 23131032
[TBL] [Abstract][Full Text] [Related]
18. The pathogenesis and treatment of acid sphingomyelinase-deficient Niemann-Pick disease.
Schuchman EH
Int J Clin Pharmacol Ther; 2009; 47 Suppl 1():S48-57. PubMed ID: 20040312
[TBL] [Abstract][Full Text] [Related]
19. Hematopoietic stem cell gene therapy leads to marked visceral organ improvements and a delayed onset of neurological abnormalities in the acid sphingomyelinase deficient mouse model of Niemann-Pick disease.
Miranda SR; Erlich S; Friedrich VL; Gatt S; Schuchman EH
Gene Ther; 2000 Oct; 7(20):1768-76. PubMed ID: 11083499
[TBL] [Abstract][Full Text] [Related]
20. Acid sphingomyelinase (Asm) deficiency patients in The Netherlands and Belgium: disease spectrum and natural course in attenuated patients.
Hollak CE; de Sonnaville ES; Cassiman D; Linthorst GE; Groener JE; Morava E; Wevers RA; Mannens M; Aerts JM; Meersseman W; Akkerman E; Niezen-Koning KE; Mulder MF; Visser G; Wijburg FA; Lefeber D; Poorthuis BJ
Mol Genet Metab; 2012 Nov; 107(3):526-33. PubMed ID: 22818240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
